Rofecoxib and Clinically Significant Upper and Lower GI Events Revisited based on documents from recent litigation.

BACKGROUND: Based on published data, it is widely believed and cited that rofecoxib use is associated with approximately a 50% reduction in significant gastrointestinal complications such as bleeding. METHODS: Data made available as part of litigation, including the VIGOR trial and an Azlheimers’ st...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Graham, David Y., Jewell, Nicholas P., Chan, Francis K.L.
Format: Artigo
Langue:Inglês
Publié: 2011
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3203315/
https://ncbi.nlm.nih.gov/pubmed/21986300
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MAJ.0b013e3182113658
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires